AV-412 is primarily utilized in the field of oncology as a potent inhibitor targeting specific tyrosine kinases, including EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2). Its application is significant in the treatment of certain types of cancers, such as lung cancer, breast cancer, and gastric cancer, particularly those driven by abnormal kinase activity. By inhibiting these kinases, AV-412 effectively disrupts the signaling pathways that promote tumor growth and proliferation. This makes it a valuable component in targeted cancer therapies, offering a more precise approach compared to traditional chemotherapy. Additionally, AV-412 is being investigated for its potential in overcoming resistance to other kinase inhibitors, enhancing its role in advanced cancer treatment strategies. Its use is often tailored to patients with specific genetic mutations that make their cancers susceptible to this form of targeted therapy. It also holds potential as a starting material for developing new anti-cancer drugs with higher efficacy and fewer side effects.